This tracker is new (launched 2026-07-30) and starts with exactly 3 entries — honestly, not padded. Each one already had a real, dated, sourced citation elsewhere in our compliance research; we didn't do fresh research to inflate the count at launch. New entries get added only when a real regulatory change is found and sourced — see the RSS feed to follow updates, or the API for machine-readable access.
Resource · Updated As It Happens
Regulation Tracker.
Dated changes to advertising regulation across the markets we work in — KKM/MOH, MDC, AHPRA/TGA, PDPA/PDPC and platform ad policy. Each entry: what changed, what it means for advertisers, and a real source.
2025-09-02 · AU · AHPRA / Medical Board of Australia
AHPRA's cosmetic procedure advertising guidelines took effect, strengthening the existing National Law s133 testimonial ban to explicitly cover influencer content and re-shared patient stories, banning appearance-prediction tools/apps, prohibiting advertising cosmetic procedures to under-18s outright, and introducing a mandatory 7-day cooling-off period for under-18 patients where a procedure is clinically appropriate at all.
What it means for advertisers: Testimonials, before/after-adjacent tools, and under-18-targeted cosmetic ads are all now explicitly out of scope for Australian cosmetic clinic advertising — compliant creative needs to convert on practitioner credibility, process transparency and education instead.
2022-10-01 · SG · PDPC (Personal Data Protection Commission), Singapore
PDPA section 48J financial penalty amendment took effect, materially raising the penalty regime for Do Not Call Registry and data-protection breaches.
What it means for advertisers: WhatsApp/SMS lead follow-up campaigns in Singapore carry meaningfully higher financial exposure for DNC violations than before this date — verifying opt-out handling and DNC registry checks is a materially higher-stakes compliance item post-amendment.
2022 · SG · MOH (Ministry of Health), Singapore
MOH Direction 02/2022 (Annex 1) — guidance for PHMCA/HCSA licensees on advertising, including restrictions on laudatory/superlative terms (§5.3(c)) and prescription-medicine naming (§4.2, Appendix A).
What it means for advertisers: Singapore clinic ad copy naming prescription products or using superlative/laudatory language ('best,' 'leading,' etc.) falls under this direction's restrictions — exact day-level date not independently confirmed beyond the document's own '02-2022' designation, stated honestly rather than guessed.
Cite this
shakalakaa (Plixitt Solutions). "Regulation Tracker." https://shakalakaa.my/resources/regulation-tracker. Updated 2026-07-30. Licensed under CC BY 4.0.